Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008, China; Institute of Clinical Pharmacology, Hunan Key Laboratory of Pharmacogenetics, Central South University, Changsha 410078, China.
Department of Pharmacognosy, School of Pharmacy, Hunan University of Chinese Medicine, Changsha, Hunan 410128, China.
J Pharm Biomed Anal. 2024 Jan 5;237:115786. doi: 10.1016/j.jpba.2023.115786. Epub 2023 Oct 11.
Ginsenosides in Panax ginseng are regarded to be functional ingredients for diverse pharmacological effects and orally administrated with very low absorption in the gastrointestinal tract to be metabolized by gut microbiota. However, in vivo metabolic characteristics of ginsenosides mediated by gut microbiota are not well-known. This study aimed to explore the metabolic profiles of ginsenosides in rat feces mediated by gut microbiota. Ginsenosides and metabolites were identified and relatively quantified by ultra-performance liquid chromatography tandem/quadrupole time-of-flight mass spectrometry (UPLC-QTOF-MS/MS). As a result, eighty-four metabolites were identified in the normal control rat feces, while only thirty intermediates were found with very low yields in the pseudo-germ-free (GF) group. Similarly, the main bioconversion pathways of ginsenosides in vivo were the same deglycosylation reaction mediated by gut microbiota in vitro. The findings demonstrated significant differences in metabolic profiles between the normal control and pseudo-GF rats, which implied gut microbiota played an important role in the metabolism of ginsenosides.
人参中的人参皂苷被认为是具有多种药理作用的功能性成分,口服后在胃肠道的吸收率非常低,会被肠道微生物群代谢。然而,肠道微生物群介导的人参皂苷的体内代谢特征尚不清楚。本研究旨在探索肠道微生物群介导的大鼠粪便中人参皂苷的代谢特征。通过超高效液相色谱串联/四极杆飞行时间质谱(UPLC-QTOF-MS/MS)对人参皂苷及其代谢产物进行了鉴定和相对定量。结果表明,在正常对照组大鼠粪便中鉴定出 84 种代谢产物,而在假无菌(GF)组中仅发现 30 种中间产物,且产量非常低。同样,体内人参皂苷的主要生物转化途径与体外肠道微生物群介导的去糖基化反应相同。这些发现表明,正常对照组和假 GF 大鼠的代谢谱存在显著差异,这表明肠道微生物群在人参皂苷的代谢中发挥了重要作用。